A Phase 3 interventional study of Vonoprazan and Amoxicillin in Helicobacter Pylori, sponsored by Takeda. Completed at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy of helicobacter pylori (HP) eradication with bismuth-containing quadruple therapy with vonoprazan versus esomeprazole in all HP-positive participants.
The drug being tested in this study is called vonoprazan (TAK-438). Vonoprazan is being tested to treat people who have helicobacter pylori infection.
The study is planned to enroll 425 patients at the beginning and will enroll a maximum of approximately 510 patients based on the interim analysis results. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
Vonoprazan 20 mg
Esomeprazole 20 mg
All participants will be asked to take one tablet in combination with bismuth containing quadruple therapy (amoxicillin, clarithromycin and bismuth potassium citrate) twice at the same time each day throughout the study.
This multi-center trial will be conducted in China. The overall time to participate in this study is 10 weeks. Participants will make multiple visits to the clinic, and 28 days after last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vonoprazan 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
Drug: Vonoprazan · Drug: Amoxicillin · Drug: Clarithromycin · Drug: Bismuth Potassium citrate
Esomeprazole 20 mg, tablets, orally, twice daily given in combination with bismuth containing quadruple therapy (amoxicillin 1 gm, capsules, clarithromycin 500 mg, tablets, and bismuth potassium citrate 600 mg) orally, twice daily for up to 2 weeks.
Drug: Amoxicillin · Drug: Clarithromycin · Drug: Bismuth Potassium citrate · Drug: Esomeprazole
Vonoprazan Tablets
Also known as: TAK-438
Amoxicillin Capsules
Clarithromycin Tablets
Bismuth Potassium citrate
Esomeprazole Tablets
Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment
HP infection status was determined by \^13C Urea Breath Test (\^13C-UBT). The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory. The percentages are rounded off to report the nearest ten.
Time frame: Week 4 post-treatment
Participants took part in the study at 29 investigative sites in China from 30 April 2020 to 25 November 2021.
| Milestone | Vonoprazan 20 mg | Esomeprazole 20 mg |
|---|---|---|
| Started | 256 | 254 |
| Completed | 254 | 252 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Voluntary withdrawal by subject | 0 | 1 |
| Withdrew: Reason not specified | 1 | 0 |
HP infection status was determined by \^13C Urea Breath Test (\^13C-UBT). The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a central laboratory. The percentages are rounded off to report the nearest ten.
| percentage of participants | Vonoprazan 20 mg | Esomeprazole 20 mg |
|---|---|---|
| Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment | 86.8 | 86.7 |
Collected over From first dose of study drug up to approximately 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vonoprazan 20 mg | 0/256 (0%) | 3/256 (1.2%) | 110/256 (43%) |
| Esomeprazole 20 mg | 0/254 (0%) | 5/254 (2%) | 91/254 (35.8%) |
| Event | Vonoprazan 20 mg | Esomeprazole 20 mg |
|---|---|---|
| Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/151 | 0/164 |
| Cervical dysplasiaReproductive system and breast disorders | 0/151 | 1/164 |
| Ovarian cyst rupturedReproductive system and breast disorders | 0/151 | 1/164 |
| Chronic gastritisGastrointestinal disorders | 0/256 | 1/254 |
| Enteritis infectiousInfections and infestations | 0/256 | 1/254 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/256 | 1/254 |
| Drug eruptionSkin and subcutaneous tissue disorders | 0/256 | 1/254 |
| Arrhythmia supraventricularCardiac disorders | 1/256 | 0/254 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/256 | 0/254 |
| Event | Vonoprazan 20 mg | Esomeprazole 20 mg |
|---|---|---|
| DysgeusiaNervous system disorders | 83/256 | 74/254 |
| Protein urine presentInvestigations | 18/256 | 15/254 |
| Hepatic function abnormalHepatobiliary disorders | 17/256 | 9/254 |
| Faeces discolouredGastrointestinal disorders | 13/256 | 8/254 |
Full analysis set (FAS) included all randomized participants who received at least 1 dose of the study drug.
| Age, Continuous(years) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| Mean | 39.5 ± 12.29 | 38.3 ± 12.13 | 38.9 ± 12.21 |
| Sex: Female, Male(Participants) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| Female | 151 | 164 | 315 |
| Male | 105 | 90 | 195 |
| Ethnicity (NIH/OMB)(Participants) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 256 | 254 | 510 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 256 | 254 | 510 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| China | 256 | 254 | 510 |
| Height(cm) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| Mean | 164.9 ± 8.23 | 164.3 ± 7.70 | 164.6 ± 7.97 |
| Weight(kg) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| Mean | 61.90 ± 10.579 | 61.15 ± 9.568 | 61.53 ± 10.087 |
| Body Mass Index (BMI)(kg/m^2) | Vonoprazan 20 mg | Esomeprazole 20 mg | Total |
|---|---|---|---|
| Mean | 22.66 ± 2.913 | 22.61 ± 2.735 | 22.63 ± 2.823 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2020 to primary completion in Nov 2021, 18 months.
Results were first posted in Sep 2023, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan